仙灵骨葆胶囊联合常规西药治疗老年骨质疏松症临床研究

Clinical Study on Xianling Gubao Capsules Combined with Routine Western Medicine for Senile Osteoporosis

目的:观察仙灵骨葆胶囊联合常规西药治疗老年骨质疏松症的临床疗效及对骨代谢标志物的影响。方法:回顾性选取102例老年骨质疏松症患者的临床资料,根据资料中治疗方式分为对照组和观察组各51例。2组患者均给予常规抗骨质疏松治疗,对照组加用鲑降钙素注射液肌肉注射治疗,观察组在对照组基础上加用仙灵骨葆胶囊口服。比较2组临床疗效,观察治疗前后中医证候评分、骨密度值、骨代谢指标及不良反应发生情况。结果:观察组总有效率为92.16%,高于对照组82.35%,差异有统计学意义(P<0.05)。治疗后,2组各项中医证候评分较治疗前降低(P<0.05),且观察组各项中医证候评分低于对照组(P<0.05)。治疗后,2组L2~4椎体、左股骨粗隆间骨密度较治疗前升高(P<0.05),且观察组治疗后L2~4椎体、左股骨粗隆间骨密度高于对照组(P<0.05)。治疗后,2组β-胶原降解产物(β-CTX)、Ⅰ型原胶原氨基端延长肽(PINP)水平较治疗前降低,25-羟基维生素(25-OHD)、骨钙素N端中分子片段(N-MID)水平较治疗前升高(P<0.05);且观察组治疗后β-CTX、PINP水平低于对照组,25-OHD、N-MID水平高于对照组(P<0.05)。观察组不良反应发生率为5.88%,低于对照组15.69%,差异有统计学意义(P<0.05)。结论:仙灵骨葆胶囊联合常规西药治疗老年骨质疏松症疗效显著,可改善患者临床症状,增加骨密度,改善骨代谢指标,降低不良反应发生率,安全可靠。

Objective:To observe the clinical effect of Xianling Gubao capsules combined with routine western medicine for senile osteoporosis and its effect on bone metabolism markers. Methods:The clinical data of 102 senile patients with osteoporosis were retrospectively selected. According to their treatment methods in the data,the patients were divided into the control group and the observation group,with 51 cases in each group. Both groups were given routine anti-osteoporosis treatment;the control group was additionally given intramuscular injection with salmon calcitonin injection, and the observation group was additionally given oral administration of Xianling Gubao capsules based on the treatment of the control group. The clinical effects in the two groups were compared. Before and after treatment, Chinese medicine syndrome scores, bone mineral density values, bone metabolism markers and incidences of adverse reactions were observed.Results:The total effective rate was 92.16% in the observation group,higher than that of 82.35% in the control group,the difference being significant(P<0.05). After treatment,Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment(P<0.05),and the scores in the observation group were lower than those in the control group(P<0.05). After treatment,the values of L2~4 vertebrae and left femur intertrochanteric bone mineral density in the two groups were increased when compared with those before treatment(P<0.05), and the above values in the observation group were increased when compared with those in the control group(P<0.05). After treatment,the levels of β-C-terminal telopeptide of type Ⅰ collagen(β-CTX) and amino-terminal propeptide of type Ⅰ procollagen(PINP) in the two groups were decreased when compared with those before treatment,and the levels of 25-hydroxy vitamin D(25-OHD) and N-terminal molecular fragments of osteocalcin(N-MID) were increased(P<0.05);the levels of β-CTX and PINP in the observation group were lower than those in the control group,and the levels of 25-OHD and N-MID were higher(P<0.05).The incidence of adverse reactions was 5.88% in the observation group,lower than that of 15.69% in the control group,the difference being significant(P<0.05). Conclusion: Xianling Gubao capsules combined with routine western medicine for senile osteoporosis has a significant curative effect, and can improve clinical symptoms, bone mineral density and bone metabolism markers,and reduce the incidence of adverse reactions,which is safe and reliable.